Table 3.
Antimicrobials most commonly used for empirical treatment of specific infections.
| Infection/Drugs | Frequency number (%)a |
Infection/Drugs | Frequency number (%)a |
|---|---|---|---|
| Early VAP (<5 days) | Suspected catheter-related bacteremia | ||
| Piperacillin/tazobactam Levofloxacin Ceftriaxone |
37/146 (25) 25/146 (17) 19/146 (13) |
Vancomycin Piperacillin/tazobactam Meropenem |
70/171 (41) 21/171 (12) 15/171 (9) |
| Late VAP (≥5 days) | Suspected candidemia and/or invasive | ||
| Piperacillin/tazobactam Meropenem Ceftazidime |
50/142 (35) 23/142 (16) 17/142 (12) |
candidiasis Fluconazole Caspofungin Voriconazole |
97/151 (64) 32/151 (21) 9/151 (6%) |
| Community-acquired pneumonia | Community-acquired peritonitis | ||
| Ceftriaxone Levofloxacin Amoxicillin/clavulanic acid |
42/156 (27) 31/156 (20) 23/156 (15) |
Piperacillin/tazobactam Ampicillin/sulbactam Cefotaxime |
37/161 (23) 26/161 (16) 16/161 (10) |
| Hospital-acquired pneumonia | Postoperative peritonitis | ||
| Piperacillin/tazobactam Levofloxacin Ceftriaxone |
51/171 (30) 26/171 (15) 22/171 (13) |
Piperacillin/tazobactam Meropenem Ertapenem |
63/165 (38) 46/165 (28) 8/165 (5) |
| Health-care-acquired pneumonia | Purulent meningitis | ||
| Piperacillin/tazobactam Meropenem Ceftazidime |
39/143 (27) 24/143 (17) 13/143 (9) |
Ceftriaxone Linezolid Cefotaxime |
111/156 (71) 6/156 (4) 6/156 (4) |
aDenominators represent the number of ICUs that answered the specific question. VAP, ventilator-associated pneumonia.